Log in

Start Your Membership Now

On September 26, 2024, the Food and Drug Administration (FDA) approved the first new drug to treat schizophrenia in more than 35 years. The drug is branded as Cobenfy. It was developed by Karuna Therapeutics, which was acquired by Bristol Myers Squibb (BMS) in March 2024. Cobenfy is an oral medication (formerly referred to as KarXT) to treat adults diagnosed with schizophrenia. In clinical trials, people who took Cobenfy had reductions in symptoms of schizophrenia without the metabolic changes and movement disorder side effects characteristic of previously approved antipsychotics.

In announcing the FDA approval, BMS also announced the launch of . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
Log In
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member
If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

Treatment Innovation & Treatment Technology